CAR-T/CAR-NKÁÆ·¨ÕýÔڸıäÖ×ÁöÖÎÁƵÄÇ°¾°£¬µ«ÆäÉú²ú±¾ÉíÒ²ÃæÁÙһϵÁÐÌôÕ½¡£Óë´ó¶àÊýÒ©Îﲻͬ£¬ÓÉÓÚCAR-TÁÆ·¨Ê¹Óû¼Õß×Ô¼ºµÄTϸ°û£¬ÊǸ߶ȸöÐÔ»¯µÄ£¬Ï¸°ûÖÎÁƲúÆ·µÄÖÊÁ¿ÔÚÅú´ÎºÍ»¼ÕßÖ®¼ä´æÔÚÏÔÖø²îÒì¡£ÔÚ¿ª·¢¹ý³ÌÖУ¬×îÖØ´óµÄÌôÕ½Ö®Ò»ÊDZíÕ÷ÖƱ¸CAR-T²úÆ·µÄÖÊÁ¿ºÍЧÁ¦¡£k8¿­·¢(Öйú)ÀûÓÃIsoPlexisµ¥Ï¸°û¹¦Äܵ°°××éѧ¼¼Êõ£¬¿Éͨ¹ýÆÀ¼Ûµ¥¸öCAR-Tϸ°ûµÄ¶à¹¦ÄÜÐÔ£¬¸ù¾ÝÆ书Äܶ¨Òåϸ°ûµÄÖÊÁ¿£¬ÓÐЧ°ïÖúÑо¿ÕߺܺõÄÓ­½ÓCAR-TÉú²ú¹¤ÒÕµÄÆÀ¹ÀºÍ¸Ä½øµÄÌôÕ½¡£

 

 

 

ͼ2  IsoLightµ¥Ï¸°ûµ°°×ÖÊ×é·ÖÎöϵͳ³ÉΪCAR-Tϸ°ûÉú²ú¹¤ÒÕÖеĹؼüÒ»»·

       Ñо¿ÈËÔ±²ÉÓÃÁËÁ½ÖÖÉú²úÖƱ¸·½·¨£¬¶Ô±ÈÁ˲»Í¬µÄ·½·¨ÖƱ¸µÄCAR-Tϸ°ûµÄ²îÒì¡£µÚÒ»ÖÖ·½·¨£¨M1£©ÔÚµÚ5ÌìÒÔÏ´µÓ²½ÖèÖÕֹתȾ£¬¶øµÚ¶þÖÖ·½·¨£¨M2£©ÔÚµÚ3ÌìÖÕֹתȾ¡£¸´ËÕµÄCAR-Tϸ°ûÓÿ¹CD4»ò¿¹CD8´ÅÖé·ÖÑ¡£¬²¢Óë±í´ïCD19»òCD22¿¹Ô­µÄ°Ðϸ°û¹²ÅàÑø¡£È¥³ý°Ðϸ°ûºó£¬½«CAR-Tϸ°ûÐüÒºÔØÈëIsoCodeµ¥Ï¸°ûµ°°×ÖÊ×éоƬ£¬²¶»ñµ¥Ï¸°ûµÄϸ°ûÒò×ÓÐźÅ£¬Êý¾ÝʹÓÃIsoSpeakÈí¼þ½øÐзÖÎö£¨Í¼ 3£©¡£

              Í¼3  Isoplexis·ÖÎöCAR-Tϸ°ûµÄ»ù±¾Á÷³Ì

       ½á¹û±íÃ÷£¬ÎÞÂÛÊÇ°ÐÏòCD19»¹ÊÇCD22µÄCD4+»òÕßCD8+µÄCAR-Tϸ°û²úÆ·£¬Ê¹ÓÃM2·½·¨ÖƱ¸µÃµ½µÄϸ°û£¬Ï¸°û¶à¹¦ÄÜÖ¸Êý¸ü¸ß(ͼ4)¡£¼´Ê¹ÓÃM2ÖƱ¸µÄCAR-T²úÆ·±íÏÖ³ö¸ü¸ßµÄ¶à¹¦ÄÜÐÔ£¬Ò²±íÏÖÔÚЧӦÐÔÒò×Ӻʹ̼¤ÐÔϸ°ûÒò×ÓµÄÔö¼Ó¡£ÕâÒ»µ¥Ï¸°û¶à¹¦ÄÜÊý¾ÝÇå³þµØ±íÃ÷£¬Óë֮ǰʹÓõÄM1Ïà±È£¬M2ÏÔÖø¸ÄÉÆÁËË«ÌØÒìÐÔCD19/CD22 CAR-Tϸ°û²úÆ·µÄ¹¦ÄÜ¡£

 Í¼4  µ¥Ï¸°û¶à¹¦ÄÜÐÔÓÃÓÚÆÀ¹À²»Í¬ÖƱ¸·½·¨µÃµ½µÄCAR-Tϸ°û²úÆ·

|   ¼¼ÊõÓÅÊÆ

       ¿¼Âǵ½Ï¸°ûÖÎÁƲúÆ·Éú³É¸úÆ·ÖÊ£¬Ï¸°ûÖÎÁÆÐÐÒµ´Óϸ°û´¦Àí¹¤×÷Á÷³Ì£¬Ï¸°û·ÖÀ롢ϸ°ûÅàÑøµ½×îÖÕϸ°û²úÎïµÄÅä·½¶¼ÐèÒª¸ü¶à×Ô¶¯»¯µÄÁ÷³Ì¡£IsoPlexisµÄIsoLightµ¥Ï¸°ûÒò×Ó¼ì²âϵͳ²ÉÓÃÈ«×Ô¶¯¼ì²âµÄ¹¤×÷·½Ê½ºÍ¶Ëµ½¶Ë(End-to-end)¹¤×÷Á÷³Ì£¬°üº¬Ï¸°ûÅàÑø£¬²¶»ñÒò×ÓÐźÅ£¬¶àÖØÒò×Ó¼ì²â£¬Ó°ÏñÊý¾Ý¶ÁÈ¡¼°µ¼³ö¡£¼òµ¥Ö±¹ÛµÄIsoSpeak¶àάÉúÐÅ·ÖÎöÈí¼þ£¬ÎÞÐèÌرðÅàѵÉúÐÅ·ÖÎöÈËÔ±À´½øÐÐÊý¾Ý·ÖÎö¡£´ó·ùÌá¸ß¹¤³Ìϸ°û²úÆ·¿ª·¢ºÍÁ÷³ÌµÄÓÅ»¯¡£

|   ¾­µä°¸Àý £¨µã»÷¿É¹Û¿´ÊÓƵ£©

      ÔçÔÚ2018ÄêһƪBloodÔÓÖ¾ÎÄÕÂÖÐÑо¿ÁËÖÎÁÆ·Ç»ôÆæ½ðÁÜ°ÍÁö(NHL)°ÐÏòCD19 CAR-Tϸ°û£¬¼ì²âÁËÔÚÊäעǰCAR-Tϸ°ûµÄ¶à¹¦ÄÜÐÔ¼°PSIÖ¸Êý£¬²¢·¢ÏÖÓëÁÙ´²½á¹ûÓÐÕýÏà¹ØÐÔ¡£Ñо¿±íÃ÷£¬ÕâЩ»¼ÕßÊäעǰCAR-TµÄ¶à¹¦ÄÜÐÔÓ뻼Õß½ÓÊÜÖÎÁƺóµÄ¿Í¹Û·´Ó¦(OR)ºÍϸ°ûÒò×ÓÊÍ·Å×ÛºÏÕ÷(CRS)¾ßÓÐͳ¼ÆѧÕýÏà¹ØÐÔ£¬Í¨¹ýµ¥Ï¸°ûÌåÍâʵÑéÄܹ»Ô¤²âÁÙ´²ÖÎÁƽá¹û¼°²»Á¼·´Ó¦¡£PSI¿ÉÒÔÓÐЧÇø·Ö¶ÔÖÎÁÆÓÐÓ¦´ðÕߺÍÎÞÓ¦´ðÕߣ¨Í¼5£©¡£

 Í¼5  CAR-Tϸ°ûPSIÓ뻼ÕßÔ¤ºó¾ßÓÐÏÔÖøÏà¹ØÐÔ

       2020ÄêGastroenterologyÔÓÖ¾·¢±íÒ»ÏîCAR-T¸ÄÁ¼·½·¨°ÐÏòʵÌåÁöµÄÑо¿¡£Ñо¿¶Ô±È·ÖÎöÁË°ÐÏò¸Îϸ°û°©¸ß±í´ï µÄGPC3Á½¸ö²»Í¬¿¹Ô­±íλµÄCAR-T¹¦Ð§¡£Ñо¿ÕßÊ×ÏÈÌåÍâʵÑé·¢ÏÖÁË°ÐÏòhYP7µÄCAR-Tϸ°û±È°ÐÏòHN3µÄCAR-Tϸ°û¾ßÓиüÇ¿µÄÖ×ÁöɱÉËÄÜÁ¦¡£ÎªÁË×ôÖ¤ÕâÒ»½á¹û£¬Ñо¿Õß²ÉÓÃÁËIsoplexisµ¥Ï¸°û¹¦Äܵ°°××é·ÖÎöÁ½ÖÖCAR-Tϸ°û£¬½á¹û·¢ÏÖÁËhYP7-CAR-Tϸ°û¾ßÓиü¸ßµÄ¶à¹¦ÄÜÐÔÖ¸Êý£¨PSI£©¡£Isoplexis·ÖÎö½á¹ûºÍÌåÍâЧÄÜÏàÒ»Ö£¬ÎªÏÂÒ»²½µÄÌåÄÚʵÑéÌṩÁËÖØÒªµÄÖÊ¿ØÆÀ¹ÀÒÀ¾Ý¡£×îÖÕµÄÌåÄÚʵÑéҲ֤ʵÁËhYP7-CAR-Tϸ°û¾ßÓиüÇ¿µÄÒÖÖƺÍÏû³ýÖ×Áöϸ°ûµÄÄÜÁ¦£¨Í¼6£©¡£

 Í¼6  µ¥Ï¸°û¹¦Äܵ°°××é×÷ΪCAR-Tϸ°û¹¦Ð§µÄÖÊÁ¿ÆÀ¹ÀÖ¸±ê

|   Ïà¹ØÎÄÏ×

[1]. Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419-1431.
[2]. McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M et al. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021;29(5):1808-1820.
[3]. Fousek K, Watanabe J, Joseph SK, George A, An X, Byrd TT et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021;35(1):75-89.
[4]. Thomas A, Sumughan S, Dellacecca ER, Shivde RS, Lancki N, Mukhatayev Z et al. Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice. JCI Insight. 2021;6(22):e152014.
[5]. Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K et al.  4-1BB and optimized CD28 co-stimulation enhances function of human monospecific­and­bispecific­third generation­CAR­T­cells. J Immunother Cancer. 2021;9(10):e003354.
[6]. Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology. 2020;158(8):2250-2265.e20.
[7]. Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019;3(21):3248-3260.
[18. Rossi J, Paczkowski P, Shen YW, Morse K, Flynn B, Kaiser A et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132(8):804-814.